Here is a list of the current clinical trials at Broward Health where we are actively enrolling patients. If you have any questions, please feel free to contact us


  • Lung
    • FDI-213: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation Small Cell Lung Cancer (PENDING)
  • Breast
    • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
    • Alliance A011502: Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial       
    • SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her2+ Breast Cancer
    • SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
    • NRG-B004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer       
  • Gynecologic
    • SGNTV-3057: A Randomized, Open-Label, Phase III Trial of Tisotumab Vedotin vs. Investigator's Choice Chemotherapy in Second- or Third- Line Recurrent or Metastatic Cervical Cancer 
    • GOG-3041/AstraZeneca: Randomized, Multicentre, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) 
  • Prostate

    NRG-GU005: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer       

  • Head and Neck 
    • EA3161: Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced Intermediate Risk HPV Positive OPCA
  • MT Group: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (Specimen Trial)    
    • MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
  • Leukemia 
    • Alliance A041702: Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 years of age) with Chronic Lymphocytic Leukemia (CLL) 
    • EA9161: Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphcytic Leukemia (CLL)
  • Anal 
    • EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • Screening 
    • EAY131: Molecular Analysis for Therapy Choice (MATCH)  
  •  Biospecimen Trials
    • Fujirebio FDI-209: A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with All Stages of Lung Cancer 
    • NSU and Broward Health Collaboration: Tissue Samples and Nucleotide Excision Repair Capacity to Evaluate the Nucleotide Excision Repair (NER) Capacity of Non-Tumor Adjacent (NTA) Tissue

      SERATRIALS - 18004: A Multi-Center Study for the Collection of Biospeciments for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research       



  • LESS-VT: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT (LESS-VT) Study
  • SOLVE CRT: Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
  • OSIRIS: Observational Study on Inappropriate Therapies after Replacement of ICDs
  • CHAMPION AF: Watchman FLX versus NOAC for Embolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation




  • AL002: Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer's Disease    


  • Can Time-Restricted Eating Improve Post Ischemic Stroke Risk Factors



  • HIV
    • PH300 AMP Up V1.0: PH300: A Multi-Center Study of the Pediatric HIV/AIDS Cohort Study (PHACS), Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) Version 1.0      
    • IMPAACT 2017 V3.0: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV Infected Children and Adolescents - MOCHA More Options for Children and Adolescents



  • Leukemia
    • AALL1631: A Children’s Oncology Protocol for an International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone   
    • AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) 
    • AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-risk B-ALL; Risk-Adapted Post-induction Therapy for High-risk B-ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy
  • Neuroblastoma
    • ANBL00B1: A Children’s Oncology Group Protocol for Biomarkers in Tumor Tissue Samples from Patients with Newly Diangosed Neuroblastoma or Ganglioneuroblastoma
  • Renal/Kidney
    • AREN03B2: A Children’s Oncology Group Protocol for Study of Kidney Tumors in Younger Patient 
    • AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy Versus Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma Across All Age Groups
  • Other
    • ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
    • APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
    • AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors 
    • APEC14B1: A Children’s Oncology Protocol for Project: EveryChild: A Registry, Eligibility Screening, Biology, and Outcome Study
    • ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
    • A031102: A Randomized Phase III Trial Comparing Conventional-dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
    • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
    • S1826: A Phase III, Randomized Study of Nivolumab (OPDIVO) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age 12 or older) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma NCT#03907488 



  • HIV
    • IMPAACT P1115 V2.0: A Very Early Intensive Treatment of HIV-1 Infected Infants to Achieve HIV Remission: A Phase I/II Proff of Concept Study
    • PH100 SMARTT V5.0: PHACS 100: Surveillance Monitoring for ART Toxicities in HIV Uninfected Children Born to HIV Infected Women (SMARTT Study). Version Change Includes SMARTT Reference Cohort Sub Study and SMARTT Nutrition Sub Study
    • (TIES) Treating Infants Early Study: V5.0 8/24/2018